Showing 6221-6230 of 9507 results for "".
- Phase 3 Data for BF-200 ALA Presented at the 14th South Beach Symposiumhttps://practicaldermatology.com/news/phase-3-data-for-bf-200-ala-presented-at-the-14th-south-beach-symposium/2458702/Biofrontera AG’s BF-200 ALA plus red light photodynamic therapy (PDT) shows good efficacy for the treatment of actinic keratoses (AK), according to data presented from three pivotal Phase III trials at the 14th Annual South Beach Symposium. The results were presented in a poster (Poster #11
- Biosimilar News: Sandoz Acquires Biosimilar Infliximab In EEA, FDA Panel Urges Approval of Biosimilar Infliximab in UShttps://practicaldermatology.com/news/biosimilar-new-sandoz-acquires-biosimilar-infliximab-in-eea-fda-panel-urges-approval-of-biosimilar-infliximab-in-us/2458705/Two days after a US Food and Drug Administration (FDA) advisory panel voted to recommend approval of the biosimilar form of Remicade (Infliximab), Novartis’ Sandoz unit has acquired rights to develop and commercialize a biosimilar to Remicade® (i
- Traffic-related Air pollution Linked to Facial Lentigeneshttps://practicaldermatology.com/news/traffic-related-air-pollution-linked-to-facial-lentigenes/2458707/High levels of traffic-related air pollution and air pollution-associated gases may increase risk of developing facial lentigenes, new research suggests. "While NO2 exposure is known to be associated with low lung function and lung cancer, the effect o
- FDA Awards Tentative Approval for Zenavod to Treat Rosaceahttps://practicaldermatology.com/news/fda-awards-tentative-approval-for-zenavod-to-treat-rosacea/2458711/The FDA awarded Dr. Reddy's Laboratories tentative approval for Zenavod™ (doxycycline) Capsules, 40mg. Zenavod is a tetracycline-class drug indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. Promius™ Pharma, LLC, t
- Pfizer Outlines Post-Allergan Deal Leadership Team Changeshttps://practicaldermatology.com/news/pfizer-outlines-post-allergan-deal-leadership-team-changes/2458709/Brent Saunders will become President and Chief Operating Officer of the combined Pfizer and Allergan company following the close of the merger deal. In this role, he will over see Pfizer and Allergan’s combined commercial businesses, manufacturing and strategy functions. The c
- SENTÉ Raises $5 million, Appoints New CEOhttps://practicaldermatology.com/news/sent-raises-5-million-appoints-new-ceo/2458713/There’s big news coming out of SENTÉ this week. Fresh of the announcement that they closed on a $5 million financing round, the company also appointed Laurent Combredet as President and Chief Executive Officer. Mr. Combredet was G
- Promius Receives FDA Approval for Sernivo Spray for Psoriasishttps://practicaldermatology.com/news/promius-receives-fda-approval-for-sernivo-spray-for-psoriasis/2458715/Dr. Reddy’s US subsidiary Promius Pharma received FDA approval for Sernivo (betamethasone dipropionate) Spray 0.05%. Sernivo Spray, a prescription topical steroid, is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older. The commercial launch
- ASDS: Cosmetic Treatments Can Correct Facial Deformities Toohttps://practicaldermatology.com/news/asds-cosmetic-treatments-can-correct-facial-deformities-too/2458714/Soft-tissue fillers, neurotoxins and lasers can be used to correct facial deformities caused by a variety of medical conditions, according to information presented at the 2015 American Society for Dermatologic Surgery meeting. During the session, Wa
- Otsuka Licenses Pre-Phase 3 Topical Atopic Dermatitis Treatment to Medimetrikshttps://practicaldermatology.com/news/otsuka-licenses-pre-phase-3-topical-atopic-dermatitis-treatment-to-medimetriks/2458712/Otsuka Pharmaceutical Co., Ltd. and Medimetriks Pharmaceuticals, Inc. have entered into a licensing agreement granting Medimetriks exclusive development, manufacturing and commercialization rights for OPA-15406 in
- Novan Announces Robert A. Ingram as Chairmanhttps://practicaldermatology.com/news/novan-announces-robert-a-ingram-as-chairman/2458716/Novan, Inc. named Robert A. Ingram as Chairman of the Board of Directors of Novan. In addition, Robert Keegan has been appointed to the Board of Directors. The company also announced that it received $32.8 million of net proceeds in a private Mezzanine B financing in December 2015 from it